Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer

Abstract

Recently, programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have achieved major breakthroughs in oncology, with 32 drugs approved over the past decade. This advancement has established immunotherapy as the fifth major antitumor modality following surgery, chemotherapy, radiotherapy, and targeted therapy. However, PD-1/PD-L1 inhibitors induce sustained responses in only a limited number of patients, and primary and acquired resistance remain critical challenges in clinical practice. As understanding of the complex crosstalk among cancer cells, the tumor microenvironment, and the host immune system deepens, numerous strategies to overcome PD-1/PD-L1 inhibitor resistance have been proposed. In this review, we examine the current development of PD-1/PD-L1 inhibitors, analyze global approval trends, and evaluate their monotherapy efficacy across various tumor types. As multi-target combination therapy is an essential strategy for overcoming resistance, we analyze key combination targets - such as vascular endothelial growth factor (VEGF), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and lymphocyte activation gene 3 (LAG-3) - and highlight the clinical success of novel dual-target regimens such as ivonescimab (PD-1/VEGF). Furthermore, we discuss potential approaches to overcoming resistance from both microenvironmental (e.g., targeting cancer-associated fibroblasts or utilizing antibody-drug conjugates) and macroenvironmental (e.g., modulating the microbiota or sex hormones) perspectives. This review provides a forward-looking framework for designing precision- and mechanism-driven combination therapies aimed at converting non-responders into responders.

Keywords

Programmed cell death protein 1 / programmed cell death ligand 1 / drug resistance

References

[1] Ishida Y,Shibahara K.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J1992;11:3887-95 PMCID:PMC556898

[2] Nishimura H,Hiai H,Honjo T.Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity1999;11:141-51

[3] Dong H,Tamada K.B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat Med1999;5:1365-9

[4] Freeman GJ,Iwai Y.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J Exp Med2000;192:1027-34 PMCID:PMC2193311

[5] Dong H,Salomao DR.Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med2002;8:793-800

[6] Iwai Y,Tanaka Y,Honjo T.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.Proc Natl Acad Sci U S A2002;99:12293-7 PMCID:PMC129438

[7] Curiel TJ,Dong H.Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.Nat Med2003;9:562-7

[8] Morad G,Sharma P.Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.Cell2022;185:576

[9] Conforti F,Di Mitri D.Sex hormones, the anticancer immune response, and therapeutic opportunities.Cancer Cell2025;43:343-60

[10] Cortellini A,Buti S.A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.J Immunother Cancer2019;7:57 PMCID:PMC6391761

[11] Blake SJ,Boursi B.Role of the microbiota in response to and recovery from cancer therapy.Nat Rev Immunol2024;24:308-25

[12] Keam SJ.Cadonilimab: first approval.Drugs2022;82:1333-9

[13] Dhillon S.Ivonescimab: first approval.Drugs2024;84:1135-42

[14] Paik J.Nivolumab plus relatlimab: first approval.Drugs2022;82:925-31

[15] Keam SJ.Iparomlimab and tuvonralimab: first approval.Drugs2025;85:699-706

[16] KEYTRUDA® (pembrolizumab) injection, for intravenous use. 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s172lbl.pdf. [Last accessed on 11 May 2026]

[17] TECENTRIQ® (atezolizumab) injection, for intravenous use. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. [Last accessed on 11 May 2026]

[18] Zhao S,Yang W.The next generation of immunotherapies for lung cancers.Nat Rev Clin Oncol2025;22:592-616

[19] Laktionov K,Stroyakovskiy D.Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.Eur J Cancer2025;217:115255

[20] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[21] Mao Y,Lv M.The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating.Cancer Immunol Immunother2023;72:2483-98 PMCID:PMC10992474

[22] Lang R,Richtig E.Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.J Eur Acad Dermatol Venereol2023;37:1799-810

[23] Kaufman HL,Hamid O.Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.J Immunother Cancer2018;6:7 PMCID:PMC5774167

[24] Yau T,Finn RS.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol2022;23:77-90

[25] Klein C,Reichert JM.The present and future of bispecific antibodies for cancer therapy.Nat Rev Drug Discov2024;23:301-19

[26] Finn RS, Qin S, Ikeda M, et al.; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[27] Reck M, Mok TSK, Nishio M, et al.; IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.Lancet Respir Med2019;7:387-401

[28] Douma LAH,Lalezari F.Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.Lancet Oncol2025;26:1676-84

[29] Motzer RJ,Agarwal N.NCCN Guidelines® Insights: kidney cancer, version 2.2024.J Natl Compr Canc Netw2024;22:4-16

[30] Xiong A,Chen J.Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.Lancet2025;405:839-49

[31] Chen Z,Jiang Z.Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.Lancet2025;406:2078-88

[32] Johnson ML, Cho BC, Luft A, et al.; POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study.J Clin Oncol2023;41:1213-27 PMCID:PMC9937097

[33] Paz-Ares L,Cobo M.First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Lancet Oncol2021;22:198-211

[34] Tawbi HA, Schadendorf D, Lipson EJ, et al.; RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N Engl J Med2022;386:24-34 PMCID:PMC9844513

[35] Merck KGaA, Darmstadt, Germany Statement on phase II study of Bintrafusp Alfa in first-line treatment of biliary tract cancer. Available from: https://www.emdgroup.com/en/news/bintrafusp-alfa-update-23-08-2021.html. [Last accessed on 11 May 2026]

[36] Cho BC,Wu YL.Bintrafusp Alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial.J Thorac Oncol2023;18:1731-42

[37] Masuda J,Tsurutani J.Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).J Immunother Cancer2023;11:e007126 PMCID:PMC10503337

[38] Spigel D,Nemunaitis J.Randomized phase 2 studies of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2).J Thorac Oncol2021;16:327-33

[39] Levy BP,Besse B.Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.Eur J Cancer2019;108:120-8

[40] Wang ZQ,Wu YY.Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.Signal Transduct Target Ther2023;8:420 PMCID:PMC10625992

[41] Nassiri F,Yefet LS.Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med2023;29:1370-8 PMCID:PMC10287560

[42] Liu S,Ma Q.OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment.Theranostics2023;13:4016-29 PMCID:PMC10405835

[43] Zhang P,Zhao J.STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.Nat Commun2023;14:1610 PMCID:PMC10036562

[44] Tsuchikama K,Ha SYY.Exploring the next generation of antibody-drug conjugates.Nat Rev Clin Oncol2024;21:203-23

[45] Rongvaux A,Harman CC.Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA.Cell2014;159:1563-77 PMCID:PMC4272443

[46] Conche C,Pešić M.Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.Gut2023;72:1774-82 PMCID:PMC10423492

[47] Tao Q,Wu J,Chen X.Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors.J Immunother Cancer2024;12:e008554 PMCID:PMC10936479

[48] Gong D,Wang Y,Hou Y.Role of ferroptosis on tumor progression and immunotherapy.Cell Death Discov2022;8:427 PMCID:PMC9605952

[49] He Z,Li F.TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.Drug Resist Updat2025;78:101171

[50] Zhou X,Liao H.Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8⁺ T cell-mediated ferroptosis in castration-resistant prostate cancer.Acta Pharm Sin B2022;12:692-707 PMCID:PMC8897216

[51] Catanzaro E,Naessens F,Krysko DV.Immunogenicity of ferroptosis in cancer: a matter of context?.Trends Cancer2024;10:407-16

[52] Wiernicki B,Pinney J.Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity.Nat Commun2022;13:3676 PMCID:PMC9237053

[53] Ma X,Liu L.CD36-mediated ferroptosis dampens intratumoral CD8⁺ T cell effector function and impairs their antitumor ability.Cell Metab2021;33:1001-12.e5 PMCID:PMC8102368

[54] Gao Z,Hou Y.Boosting the synergism between cancer ferroptosis and immunotherapy via targeted stimuli-responsive liposomes.Biomaterials2024;305:122442

[55] Wu B,Kong N,Li S.Engineering modular peptide nanoparticles for ferroptosis-enhanced tumor immunotherapy.Angew Chem Int Ed Engl2025;64:e202421703

[56] Yan C,Zhao G.Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy.Acta Pharm Sin B2024;14:2281-97 PMCID:PMC11119570

[57] Ribas A,Kirkwood JM.Overcoming PD-1 blockade resistance with CpG-A Toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma.Cancer Discov2021;11:2998-3007 PMCID:PMC8799774

[58] Curigliano G,Shimizu T.A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies.ESMO Open2024;9:103643 PMCID:PMC11345372

[59] Yu X,Chen B.PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.J Immunother Cancer2022;10:e004590 PMCID:PMC9577932

[60] Braun DA,Chea V.A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.Nature2025;639:474-82 PMCID:PMC11903305

[61] Weber JS,Khattak A.Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Lancet2024;403:632-44

[62] Sánchez-Paulete AR,Martínez-López M.Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells.Cancer Discov2016;6:71-9 PMCID:PMC5036540

[63] Zhou J,Zhou H.STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity.Nature2025;643:519-28 PMCID:PMC12240842

[64] Jiang Y,Zhang YW.Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.Nat Commun2024;15:2484 PMCID:PMC10954759

[65] Khushalani NI,Ferris RL.Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.J Immunother Cancer2024;12:e007364 PMCID:PMC10921538

[66] Majocchi S,Nouveau L.NI-3201 is a bispecific antibody mediating PD-L1-dependent CD28 co-stimulation on T cells for enhanced tumor control.Cancer Immunol Res2025;13:365-83 PMCID:PMC11876958

[67] Yang Z,Zhu J.Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1.Cancer Cell2025;43:86-102.e10

[68] Hwang BJ,Acharya CR.Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.J Immunother Cancer2022;10:e003721 PMCID:PMC8971789

[69] Zhuang Q,Xu X.RNA methyltransferase FTSJ3 regulates the type I interferon pathway to promote hepatocellular carcinoma immune evasion.Cancer Res2024;84:405-18

[70] Bule P,Aires-Da-Silva F.Chemokine-directed tumor microenvironment modulation in cancer immunotherapy.Int J Mol Sci2021;22:9804 PMCID:PMC8464715

[71] Yang L,Yu W.Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer.Drug Resist Updat2025;78:101175

[72] Doi T,Ishii H.A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors.Clin Cancer Res2019;25:6614-22

[73] Bockorny B,Macarulla T.BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.Nat Med2020;26:878-85

[74] Bergeron P,Sitterle L.Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade.Nat Commun2024;15:8845 PMCID:PMC11471822

[75] Jie X,Zhao Y.Targeting KDM4C enhances CD8⁺ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer.J Immunother Cancer2022;10:e003716 PMCID:PMC8819819

[76] Jiang W,Sun H.WNT11 promotes immune evasion and resistance to anti-PD-1 therapy in liver metastasis.Nat Commun2025;16:1429 PMCID:PMC11806061

[77] Lee HJ,Oh SJ.Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.Nat Commun2022;13:2127 PMCID:PMC9019109

[78] An D,Cheng WY.LTβR agonism promotes antitumor immune responses via modulation of the tumor microenvironment.Cancer Res2024;84:3984-4001

[79] Plaschka M,Grimont M.ZEB1 transcription factor promotes immune escape in melanoma.J Immunother Cancer2022;10:e003484 PMCID:PMC8921918

[80] Kuo HY,Kerbel RS.Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.Nat Rev Clin Oncol2024;21:468-82

[81] Rapisarda A.Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.Nat Rev Clin Oncol2012;9:378-90

[82] Arjaans M,Oosting SF,Kleibeuker JE.VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.Oncotarget2016;7:21247-58 PMCID:PMC5008282

[83] Guelfi S,Bergers G.Targeting the tumour vasculature: from vessel destruction to promotion.Nat Rev Cancer2024;24:655-75

[84] Huang Y,Righi E.Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.Proc Natl Acad Sci U S A2012;109:17561-6 PMCID:PMC3491458

[85] Lan J,Li Z.Biomimetic nanomodulators with synergism of photothermal therapy and vessel normalization for boosting potent anticancer immunity.Adv Mater2024;36:e2408511

[86] Schmittnaegel M,Kadioglu E.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.Sci Transl Med2017;9:eaak9670

[87] Liu Y,Kang Z.Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.Acta Pharm Sin B2023;13:4748-64 PMCID:PMC10692396

[88] Zhang Y,Pan D.Dendritic polymer-based nanomedicines remodel the tumor stroma: improve drug penetration and enhance antitumor immune response.Adv Mater2024;36:e2401304

[89] Gan L,Lu Y.Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8⁺ T cell infiltration.J Immunother Cancer2024;12:e009111 PMCID:PMC11535718

[90] Saatci O,Raza U.Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.Nat Commun2020;11:2416 PMCID:PMC7229173

[91] Lee CJ,Jeon SE.The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression.Nat Commun2024;15:10422 PMCID:PMC11607440

[92] Sun X,Chiang HC.Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion.Nature2021;599:673-8 PMCID:PMC8839149

[93] Zhang G,Yang C.A novel role of breast cancer-derived hyaluronan on inducement of M2-like tumor-associated macrophages formation.Oncoimmunology2016;5:e1172154 PMCID:PMC4938366

[94] Blair AB,Davelaar J.Dual stromal targeting sensitizes pancreatic adenocarcinoma for anti-programmed cell death protein 1 therapy.Gastroenterology2022;163:1267-80.e7 PMCID:PMC9613523

[95] Ishihara J,Ishihara A.Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.Sci Transl Med2017;9:eaan0401

[96] Bhandari C,Shah N.PD-L1 immune checkpoint targeted photoactivable liposomes (iTPALs) prime the stroma of pancreatic tumors and promote self-delivery.Adv Healthc Mater2024;13:e2304340 PMCID:PMC11281872

[97] Fattori S,Houacine J.CD25high effector regulatory T cells hamper responses to PD-1 blockade in triple-negative breast cancer.Cancer Res2023;83:3026-44 PMCID:PMC10502453

[98] Redin E,Lozano T.SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.J Immunother Cancer2021;9:e001496 PMCID:PMC7931761

[99] Meng Y,Nie P.Immunosuppressive CD10⁺ALPL⁺ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.J Hepatol2023;79:1435-49

[100] DeNardo DG.Macrophages as regulators of tumour immunity and immunotherapy.Nat Rev Immunol2019;19:369-82 PMCID:PMC7339861

[101] Larroquette M,Besse B.Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.J Immunother Cancer2022;10:e003890 PMCID:PMC9125754

[102] Cousin S,Shitara K.Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics.Mol Cancer2024;23:197 PMCID:PMC11396962

[103] Ajith A,Horuzsko DD.Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.J Clin Invest2023;133:e167951 PMCID:PMC10617775

[104] Prasad M,Jagadeeshan S.MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.J Immunother Cancer2022;10:e003917 PMCID:PMC8928405

[105] Voissière A,Chabaud S.The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.Sci Transl Med2024;16:eadd1834

[106] Yue T,Zhu J.Hydrogen sulfide creates a favorable immune microenvironment for colon cancer.Cancer Res2023;83:595-612

[107] Boelaars K,Wang D.Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.J Immunother Cancer2023;11:e007805 PMCID:PMC10632901

[108] Bell HN,Singhal R.Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer.Cell Metab2023;35:134-49.e6 PMCID:PMC9841369

[109] Zhang J,Guo X.Arginine supplementation targeting tumor-killing immune cells reconstructs the tumor microenvironment and enhances the antitumor immune response.ACS Nano2022;16:12964-78

[110] Zang J,Zheng X.Dynamic tagging to drive arginine nano-assembly to metabolically potentiate immune checkpoint blockade therapy.Biomaterials2023;292:121938

[111] Jin XK,Liang JL.A PD-L1-targeting regulator for metabolic reprogramming to enhance glutamine inhibition-mediated synergistic antitumor metabolic and immune therapy.Adv Mater2024;36:e2309094

[112] Wang W,Jiang J.Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments.Nat Commun2022;13:4495 PMCID:PMC9345862

[113] Chen N,Liu H.Enhancing PD-1 blockade in NSCLC: reprogramming tumor immune microenvironment with albumin-bound statins targeting lipid rafts and mitochondrial respiration.Bioact Mater2025;49:140-53 PMCID:PMC11930202

[114] Liu X,Hu M.Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.Nature2020;588:693-8 PMCID:PMC7770056

[115] Li L,Chao Z.Targeting Alpha-ketoglutarate disruption overcomes immunoevasion and improves PD-1 blockade immunotherapy in renal cell carcinoma.Adv Sci2023;10:e2301975 PMCID:PMC10520657

[116] Zheng X,Deng M.G3BP1 and SLU7 jointly promote immune evasion by downregulating MHC-I via PI3K/Akt activation in bladder cancer.Adv Sci2024;11:e2305922 PMCID:PMC10870071

[117] Cheng C,Sun L.VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8⁺T cells function in the HCC microenvironment.Signal Transduct Target Ther2025;10:26 PMCID:PMC11758394

[118] Grosser R,Chintala N.Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors.Cancer Cell2019;36:471-82 PMCID:PMC7171534

[119] Giuffrida L,Henderson MA.IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors.Mol Ther2020;28:2379-93 PMCID:PMC7647667

[120] Hegewisch-Becker S,Chao J.First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 study.J Clin Oncol2024;42:2080-93 PMCID:PMC11191068

[121] Son W,Park Y.Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8⁺ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment.J Immunother Cancer2025;13:e010728 PMCID:PMC12083285

[122] Hu Y,Bertolet G.Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.J Nanobiotechnology2022;20:417 PMCID:PMC9484155

[123] Dolan M,Ringel AE,McAllister SS.Ageing, immune fitness and cancer.Nat Rev Cancer2025;25:848-72

[124] Anobile DP,Tabbò F.Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune checkpoint inhibitors in non-small cell lung cancer.Clin Cancer Res2023;29:3958-73

[125] Chakraborty B,Shepherd J.Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.J Clin Invest2021;131:e151347 PMCID:PMC8631601

[126] Adurthi S,Vinodkumar HS.Oestrogen receptor-α binds the FOXP3 promoter and modulates regulatory T-cell function in human cervical cancer.Sci Rep2017;7:17289 PMCID:PMC5725534

[127] Svoronos N,Allegrezza MJ.Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells.Cancer Discov2017;7:72-85 PMCID:PMC5222699

[128] Milette S,Perrino S.Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases.Nat Commun2019;10:5745 PMCID:PMC6917725

[129] Artham S,Goyal A.Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth.Sci Adv2024;10:eadp2442 PMCID:PMC11430468

[130] Kwon Y.Potential pro-tumorigenic effect of bisphenol A in breast cancer via altering the tumor microenvironment.Cancers2022;14:3021 PMCID:PMC9221131

[131] Klinge CM.Estrogenic control of mitochondrial function.Redox Biol2020;31:101435 PMCID:PMC7212490

[132] Yuan B,Wu B.Estrogen receptor beta signaling in CD8⁺ T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch.J Immunother Cancer2021;9:e001932 PMCID:PMC7816924

[133] Guan X,Wang C.Androgen receptor activity in T cells limits checkpoint blockade efficacy.Nature2022;606:791-6 PMCID:PMC10294141

[134] Kwon H,Song NJ.Androgen conspires with the CD8⁺ T cell exhaustion program and contributes to sex bias in cancer.Sci Immunol2022;7:eabq2630 PMCID:PMC9374385

[135] Liu Q,Meng J.Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.Cancer Gene Ther2022;29:1988-2000 PMCID:PMC9750871

[136] Jin WB, Xiao L, Jeong M, et al.; JRI IBD Live Cell Bank Consortium. Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity.Cell2025;188:2336-53.e38 PMCID:PMC12439225

[137] Madi A,Su M.DGAT1 mediates sex-specific CD8⁺ T cell antitumour responses.Nat Metab2026;8:685-703

[138] Zitvogel L,Kroemer G.Long-distance microbial mechanisms impacting cancer immunosurveillance.Immunity2024;57:2013-29

[139] Sivan A,Hubert N.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science2015;350:1084-9 PMCID:PMC4873287

[140] Fidelle M,Alves Costa Silva C.A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.Science2023;380:eabo2296

[141] Park JS,Wu M.Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.Nature2023;617:377-85 PMCID:PMC10219577

[142] Najar TA,Hao Y.Microbiota-induced T cell plasticity enables immune-mediated tumour control.Nature2026;651:201-10 PMCID:PMC12960244

[143] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[144] Davar D,McCulloch JA.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science2021;371:595-602 PMCID:PMC8097968

[145] Zhou H,Nie X.A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.Nat Microbiol2026;11:993-1007

[146] Fu A,Dong T.Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer.Cell2022;185:1356-72.e26

[147] Sahler JM,Altier C.Salmonella enterica serovar typhimurium increases functional PD-L1 synergistically with gamma interferon in intestinal epithelial cells via Salmonella pathogenicity island 2.Infect Immun2018;86:e00674-17 PMCID:PMC5913837

[148] Wu YY,Cheng KS.Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection.Clin Exp Immunol2010;161:551-9 PMCID:PMC2962974

[149] Hezaveh K,Klötgen A.Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity.Immunity2022;55:324-40.e8 PMCID:PMC8888129

[150] Nejman D,Fuks G.The human tumor microbiome is composed of tumor type-specific intracellular bacteria.Science2020;368:973-80 PMCID:PMC7757858

[151] Chen J,Chen Y.Identification and validation of intratumoral microbiome associated with sensitization to immune checkpoint inhibitors.Cell Rep Med2025;6:102306 PMCID:PMC12490247

[152] Canale FP,Antonini G.Metabolic modulation of tumours with engineered bacteria for immunotherapy.Nature2021;598:662-6

[153] Murphy S,Gan D.Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.Cancer Res2024;84:1597-612 PMCID:PMC11096030

[154] Fiuza-Luces C,Gálvez BG.The effect of physical exercise on anticancer immunity.Nat Rev Immunol2024;24:282-93

[155] Geng Q,Shen Z.Norepinephrine inhibits CD8⁺ T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma.Br J Cancer2023;128:1223-35 PMCID:PMC10050078

[156] Qiao G,Mohammadpour H.Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment.Cancer Immunol Res2021;9:651-64 PMCID:PMC8355045

[157] Yan X,Li D.Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors.Int Immunopharmacol2022;113:109383

[158] Zhu J,Boudhan L,Gatto L.Tumour immune rejection triggered by activation of α2-adrenergic receptors.Nature2023;618:607-15

[159] Yang J,Lv X.Neurotransmitters: an emerging target for therapeutic resistance to tumor immune checkpoint inhibitors.Mol Cancer2025;24:216 PMCID:PMC12337524

[160] Schneider MA,Beffinger MM.Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.Sci Transl Med2021;13:eabc8188

[161] Balood M,Eichwald T.Nociceptor neurons affect cancer immunosurveillance.Nature2022;611:405-12 PMCID:PMC9646485

[162] Amit M,Roger A.Neuro-immune cross-talk in cancer.Nat Rev Cancer2025;25:573-89 PMCID:PMC13142818